Abstract
1,4-Butanediol (BD), a substance of abuse, is bioactivated to γ-hydroxybutyrate (GHB), but its fundamental pharmacokinetics (PK) have not been characterized. Because this bioactivation is partly mediated by alcohol dehydrogenase, we hypothesized that there may also be a metabolic interaction between ethanol (ETOH) and BD. We therefore studied, in rats, the plasma PK of GHB, BD and ETOH each at two intravenous (IV) doses, when each substance was given alone, and when GHB or BD was co-administered with ETOH. Results showed that bioconversion of intravenously administered BD to GHB was complete, and that both GHB and BD exhibited nonlinear PK. Various population PK models were analyzed using NONMEM VI, and the best disposition model was found to include two PK compartments each for BD, an (unmeasured) putative semialdehyde intermediate (ALD), GHB and ETOH, the presence of nonlinear (Michaelis–Menten) elimination for each compound, and several mutual inhibition processes. The most prominent mutual metabolic inhibition was found between ETOH and BD, while that between GHB and ETOH was not significant. In vitro studies using liver homogenates confirmed mutual metabolic inhibitions between GHB and BD. Oral absorption of BD was best described by a first-order process with lag-time and pre-systemic metabolism from BD to ALD. Oral absorption of BD (as BD plus ALD) was rapid and complete. The fraction of the absorbed dose entering the central compartment as BD was 30% for the 1.58 mmol/kg dose and 55% for the 6.34 mmol/kg dose. At 6.34 mmol/kg IV, the onset of loss of righting reflex (LRR) for BD was significantly delayed vs. that produced by GHB (72.0 ± 9.1 min vs. 6.7 ± 0.6 min, respectively, p < 0.001), and the total duration of LRR was prolonged for BD vs. GHB (192 ± 28 min vs. 117 ± 2 min, respectively, p < 0.05). Relative to IV dosing, oral BD produced similar but more variable LRR effects. These results may provide a quantitative PK framework for the understanding of the toxicokinetics and toxicodynamics of both BD and GHB.
Similar content being viewed by others
References
A. Camacho, S. C. Matthews, B. Murray, and J. E. Dimsdale. Use of GHB compounds among college students. Am. J. Drug Alcohol Abuse 31(4):601–607 (2005).
J. Lettieri, and H. L. Fung. Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid. Res. Commun. Chem. Pathol. Pharmacol. 13(3):425–437 (1976).
J. Lettieri, and H. L. Fung. Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res. Commun. Chem. Pathol. Pharmacol. 22(1):107–118 (1978).
J. T. Lettieri, and H. L. Fung. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J. Pharmacol. Exp. Ther. 208(1):7–11 (1979).
R. D. Irwin. NTP summary report on the metabolism, disposition, and toxicity of 1,4-butanediol (CAS No. 110-63-4). Toxic. Rep. Ser. 54:1–28, A21–28, B21–25 (1996).
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193(1):265–275 (1951).
K. M. Boje, and H. L. Fung. Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat. J. Pharmacol. Exp. Ther. 249(2):567–571 (1989).
S. L. Beal, L. B. Sheiner, A. J. Boechmann (eds.). NONMEM Users Guides. Version 6, Icon Development Solutions, Ellicott City, 1989–2006.
H. L. Fung, E. Haas, J. Raybon, J. Xu, and S. M. Fung. Liquid chromatographic-mass spectrometric determination of endogenous gamma-hydroxybutyrate concentrations in rat brain regions and plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 807(2):287–291 (2004).
D. K. Van Sassenbroeck, P. De Paepe, F. M. Belpaire, and W. A. Buylaert. Characterization of the pharmacokinetic and pharmacodynamic interaction between gamma-hydroxybutyrate and ethanol in the rat. Toxicol. Sci. 73(2):270–278 (2003).
H. Matsumoto, T. Fujimiya, and Y. Fukui. Role of alcohol dehydrogenase in rat ethanol elimination kinetics. Alcohol Alcohol Suppl. 29(1):15–20 (1994).
J. Shimada, T. Miyahara, S. Otsubo, N. Yoshimatsu, T. Oguma, and T. Matsubara. Effects of alcohol-metabolizing enzyme inhibitors and beta-lactam antibiotics on ethanol elimination in rats. Jpn. J. Pharmacol. 45(4):533–544 (1987).
M. S. Mumenthaler, J. L. Taylor, and J. A. Yesavage. Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. Alcohol Clin. Exp. Res. 24(9):1353–1362 (2000).
H. Matsumoto, Y. Minowa, Y. Nishitani, and Y. Fukui. An allometric model for predicting blood ethanol elimination in mammals. Biochem. Pharmacol. 57(2):219–223 (1999).
J. G. Wagner, P. K. Wilkinson, and D. A. Ganes. Parameters Vm' and Km for elimination of alcohol in young male subjects following low doses of alcohol. Alcohol Alcohol 24(6):555–564 (1989).
F. Poldrugo, and O. C. Snead 3rd. 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 3(6):367–370 (1986).
F. Poldrugo, S. Barker, M. Basa, F. Mallardi, and O. C. Snead. Ethanol potentiates the toxic effects of 1,4-butanediol. Alcohol Clin. Exp. Res. 9(6):493–497 (1985).
F. Poldrugo, and O. C. Snead 3rd. Effect of ethanol and acetaldehyde on gamma-hydroxybutyric acid in rat brain and liver. Subst. Alcohol Actions Misuse 5(5):263–271 (1984).
W. J. Jusko, J. R. Koup, and G. Alvan. Nonlinear assessment of phenytoin bioavailability. J. Pharmacokinet. Biopharm. 4(4):327–336 (1976).
Acknowledgements
This work was supported in part by NIH grant DA14988.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fung, HL., Tsou, PS., Bulitta, J.B. et al. Pharmacokinetics of 1,4-Butanediol in Rats: Bioactivation to γ-Hydroxybutyric Acid, Interaction with Ethanol, and Oral Bioavailability. AAPS J 10, 56–69 (2008). https://doi.org/10.1208/s12248-007-9006-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-007-9006-3